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The importance of patient adherence for optimizing the 
benefits from medical products and interventions has 
been emphasized by World Health Organization and 
European Union initiatives.1,2 Approximately 50% of 
patients with medical conditions do not adhere to treat-
ment; although influenced by specific disease and type 
of treatment, adherence rates are even lower among 
patients with chronic illness.1-3 With frequent approvals 
of easily administered but potentially risky new treat-
ments in multiple sclerosis (MS), exploring how patients’ 
orientate themselves to decision-making processes about 
treatment as well as their subsequent treatment adher-
ence becomes increasingly important. To date, most 
treatment-related research in MS has explored factors 
associated with medication adherence. Medications 
comprise an important part of treatment, but behavioural 
interventions have demonstrated effectiveness and are 
increasingly utilized. Consequently, adherence to behav-
ioural interventions such as physical rehabilitation and 
psychotherapy is also important for sustaining patients’ 
quality of life and autonomy. Within this context, across 
all medical conditions very few effective interventions 
to improve adherence exist, and focussed, interdiscipli-
nary research is needed.4
An exploratory meeting (17 April 2013) convened 
under the auspices of the European Rehabilitation in 
MS (RIMS) network was held with clinicians, 
researchers, patient representatives, and other stake-
holders. The goal was to summarize the current 
knowledge on adherence in MS and to identify first 
steps towards developing an ongoing research agenda.
The first part of the meeting consisted of participants’ 
short presentations about adherence in general and in 
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MS. Within the meeting, a structured focus group 
with the participants (n=20) was used to compile 
future research and care prospects for adherence in 
MS (for detailed group information see participant list 
below). By including patients, scientists, and public 
involvement, the group made an effort to incorporate 
multiple perspectives. A list of core questions was 
devised by the facilitators (PB and WC) and the focus 
group lasted for 90 minutes.
Summary of presentations
The terms compliance, adherence, persistence, and 
concordance have often been used interchangeably in 
the literature on medicines adherence. However, these 
terms have different meanings and, to some extent, 
reflect different perspectives and priorities in relation 
to the overall process of prescribing and medicines 
usage. The term compliance has been associated with 
a paternalistic healthcare approach based on the con-
cept that patients need to follow rules. When patients’ 
actions do not match the expectations placed on them 
by health professionals they are non-compliant. 
Adherence allows for the active agreement, consent, 
and involvement of the patient who is prescribed 
medication. Concordance was introduced to describe 
a collaborative or shared process of discussion and 
decision-making between the patient and healthcare 
provider. However, even after 15 years of research 
and practice, the efficacy of shared decision-making 
remains difficult to determine.5 The ADAMS group 
suggests the term ‘adherence’, as it offers the most 
practical term in the field, integrating concordance, 
and offering approaches for evaluation and measure-
ment. Non-adherence may be subdivided into inten-
tional and non-intentional facets. Furthermore, 
non-adherence can be split into inconsistent imple-
mentation (e.g. missing doses) and treatment interrup-
tion or stopping, which is also referred to as lack of 
treatment persistence.2 These differences are often not 
clearly delineated in MS adherence research studies.
Various theoretical models have been developed to 
better understand behaviour change and treatment 
adherence in healthcare settings. However, none of 
these models alone captures all aspects of behaviour 
change and treatment adherence. The WHO report1 
addresses five major domains being relevant: condi-
tion-related, patient-related, treatment-related, socio-
economic as well as health system-related factors. 
These factors need to be explored when modelling a 
behaviour change intervention. Recently, the British 
National Institute for Health and Care Excellence 
(NICE) has issued a guideline on individual behav-
iour change approaches.6
In MS, drug treatment discontinuation rates range from 
16% up to 50% or higher depending on the methodol-
ogy used in studies, including length and manner of 
adherence monitoring (for review see elsewhere7,8). In 
addition, though there is no agreed gold standard for 
the percentage of doses needed for therapeutic effec-
tiveness, 1 in 5 patients continuing to take medication 
miss more than 20% of their prescribed doses.9 Major 
reasons for inconsistent use may be non-intentional 
(e.g. forgetfulness, general fatigue, emotional distress). 
Side effects also play an important role. Major reasons 
for treatment discontinuation include adverse events 
and perceived lack of treatment efficacy. Unrealistic 
treatment expectations and critical views on medica-
tion in general have been found to predict lack of per-
sistence. However, as MS treatments are only partially 
effective, perceived lack of efficacy sometimes over-
laps with objective breakthrough disease. In addition, 
other psychological factors such as depression, self-
efficacy, hope, and physician trust play a role in adher-
ence.10 Interestingly, Riñon et al.11 found substantial 
differences between patients’ and physicians’ percep-
tions of adherence. Although patients commonly 
reported non-adherence, 59% of physicians did not 
consider adherence to be a problem.
Little research has been undertaken in the area of 
adherence to rehabilitative interventions or symp-
tom-oriented drug treatments in MS. The same holds 
true for behavioural interventions addressing psycho-
logical, neuropsychological, or psychiatric symp-
toms in MS.
In MS, very few systematic studies have investigated 
the effectiveness of adherence interventions. Perceived 
efficacy and side effects should be priority areas to 
address in intervention studies, given their known 
association with treatment adherence in MS. The 
timely use of carefully developed and administered 
evidence-based educational tools might be the best 
approach to prevent misplaced expectations and to 
reach agreement on medication efficacy between 
patients and physicians. A recent trial has shown that 
this approach might increase adherence.12
Injection aids, co-medications, and alternative oral 
immunotherapies are now available to ameliorate or 
eliminate injection site reactions. Information and 
low-barrier access to expert support may also aid 
adherence. However, even with the most elaborate 
interventions, problems may persist. Pilot work utiliz-
ing motivational interviewing, a collaborate style of 
talk therapy that respects the patient’s perspectives and 
encourages autonomy, is currently underway. Having 
demonstrated some success improving adherence 
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among patients with Human Immunodeficiency 
Virus,13 motivational interviewing may also increase 
healthcare utilization among MS patients who prema-
turely discontinue treatments.14
Focus group results
The focus group outlined a diverse range of research 
questions and approaches around use of medicines. 
Although there was no clear consensus on a research 
agenda, four different domains for research emerged 
(details are given in Table 1):
1. Focussing the patient and their informal team
2. Describing the role of health professionals
3. Reviewing the evidence
4. Testing new interventions
These topics need to be examined in a rigorous way as 
part of a sustained collaborative effort. In addition, 
survey work might be useful to engage a larger com-
munity of health experts as well as patients and other 
stakeholders.
Conclusions
Participants agreed on the term ‘adherence’ as most 
appropriate for use in MS. It was also agreed that treat-
ment adherence is a major issue in MS and systematic 
approaches to describe, assess and modify adherence 
patterns are needed. Because adherence starts with the 
decision to change a health behaviour, understanding 
patients’ preferences and needs is of the utmost impor-
tance. Physicians can lack insight about what their 
patients value and prefer.13 Providing education and 
establishing patient preferences for treatment may be an 
appropriate starting point. The NICE guidelines on 
adherence14 strongly advocate for patient involvement 
in decision-making about treatments to support medica-
tion adherence. Furthermore, major emphasis is placed 
on routinely assessing non-adherence as a common 
problem in a non-judgemental way. To summarize, 
whilst efficacious medical and behavioural interven-
tions and products for MS are increasingly available, 
researchers need to develop a better understanding of 
how patients can consistently utilize health resources. 
Adherence to interventions not drug-related was not 
discussed in detail, and will be the focus in a second 
meeting.
Participants
Three neurologists (JSG, AS, CH), three psycholo-
gists (LE, JB, WC), one sociologist (PB), two MS 
nurse specialists (ARP, VM), one physiotherapist 
(PF), one health scientist (SK), one rehab scientist 
(MA), three patient representatives, one patient advo-
cate and five industry representatives.
Conflict of interest
CH has received speaker honoraria form Biogen Idec, 
Genzyme. He has received study grant for MS health 
care reserach from Novartis Pharma, Biogen Idec.
Table 1. Research questions and approaches.
Understanding medicines use – people with MS and informal caregivers
 ●  Understanding patient decision-making, treatment practice and factors shaping adherence to treatment in socio-
demographic context and longitudinally.
 ●  To what extent do people with MS adhere or non-adhere at different points in time across the trajectory of disease, 
and what predicts that non-adherence?
 ● What motivates or influences patients to switch disease-modifying treatments?
 ● Understanding the impact of co-morbidities.
 ●  What is the range of ways in which informal caregivers (family members, partners, friends, relatives) support 
patients with MS with medicines?
Understanding medicines use – the role of healthcare professionals
 ●  Clarify characteristics of direct care (neurologists, nurses, general medical practitioners) and allied care 
(pharmacists, psychologists, physical/occupational therapists) health professionals that support adherence.
Understanding medicines use – current practice and processes
 ● Reviewing and synthesizing treatment practices and approaches across different countries.
Behaviour change interventions to support medicines adherence
 ●  Plan and conduct trials comparing patient information leaflets and patient decision aids and their impact on patient 
adherence (and the context and effectiveness of their use).
 ● Does MS self-management training influence adherence with treatment?
 ● Exploring the use of telehealth / mobile technologies and how they could enhance adherence with treatment.
 ●  Understanding how altered communication strategies in consultations between health professionals and MS  
patients shape patient adherence with treatment.
 ●  Does personalized feedback and counselling on medicines taking enhance adherence?
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